MBRX

Maxim Group analyst Jason McCarthy maintained a Buy rating on Moleculin Biotech (MBRX – Research Report) yesterday and set a price target of $5.00. The company's shares closed last Friday at $1.67. According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of -42.3% and a 10.9% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Brooklyn ImmunoTherapeutics, and SELLAS Life Sciences Group. Currently, the analyst consensus on Moleculin Biotech is a Moderate Buy with an average price target of $9.50, representing a 452.3% upside.
https://www.tipranks.com/news/blurbs/maxim-group-keeps-their-buy-rating-on-moleculin-biotech-mbrx?utm_source=advfn.com&utm_medium=referral